



Subject: Evaluation of Measurable Residual Disease in B-Lymphoblastic Leukemia:
References Included in the Evidence Tables

1. Ahn WK, Yu K, Kim H et al. Monitoring measurable residual disease in paediatric acute lymphoblastic leukaemia using immunoglobulin gene clonality based on next-generation sequencing. *Cancer Cell Int*. 2024;24(1):218.doi:10.1186/s12935-024-03404-3
2. Ashouri K, Nittur V, Ginosyan AA et al. Concordance of next-generation sequencing and multiparametric flow cytometry methods for detecting measurable residual disease in adult acute lymphoblastic leukemia: Optimizing prediction of clinical outcomes from a single-center study. *Clin Lymphoma Myeloma Leuk*. 2024;24(3): e59-e66 e52. doi:10.1016/j.clml.2023.11.002
3. Bommannan K, Singh Sachdeva MU, Varma N, Bose P, Bansal D. Role of mid-induction peripheral blood minimal residual disease detection in pediatric b-lineage acute lymphoblastic leukemia. *Indian Pediatr*. 2016;53(12):1065-1068. <https://www.ncbi.nlm.nih.gov/pubmed/27889709>
4. Chen H, Gu M, Liang J et al. Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric b-all. *Nat Commun*. 2023;14(1):7468.doi:10.1038/s41467-023-43171-9
5. Cheng S, Inghirami G, Cheng S, Tam W. Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in b-all. *J Hematol Oncol*. 2018;11(1):105.doi:10.1186/s13045-018-0652-y
6. Chowdhury S, Bandyopadhyay S, Mandal C, Chandra S, Mandal C. Flow-cytometric monitoring of disease-associated expression of 9-o-acetylated sialoglycoproteins in combination with known cd antigens, as an index for MRD in children with acute lymphoblastic leukaemia: A two-year longitudinal follow-up study. *BMC Cancer*. 2008;8:40.doi:10.1186/1471-2407-8-40
7. Correia RP, Puga RD, Muto NH et al. High-throughput sequencing of immunoglobulin heavy chain for minimal residual disease detection in b-lymphoblastic leukemia. *Int J Lab Hematol*. 2021;43(4):724-731.doi:10.1111/ijlh.13453
8. Fossat C, Roussel M, Amoux I et al. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study. *Cytometry B Clin Cytom*. 2014;01:01.doi:10.1002/cytob.21195
9. Huang A, Huang C, Tang G et al. Impact of clinical utility of MRD assessment with different techniques on survival in acute b lymphoblastic leukemia. *Leuk Lymphoma*. 2018;59(5):1073-1083.doi:10.1080/10428194.2017.1369072
10. Huang YJ, Chen SH, Liu HC et al. Evaluation of next-generation sequencing for measurable residual disease monitoring in three major fusion transcript subtypes of b-precursor acute lymphoblastic leukaemia. *Pathology*. 2024;56(5):681-687.doi:10.1016/j.pathol.2024.02.008
11. Hwang SM, Oh I, Kwon SR, Lee JS, Seong MW. Comparison of measurable residual disease in pediatric b-lymphoblastic leukemia using multiparametric flow cytometry and next-generation sequencing. *Ann Lab Med*. 2024;44(4):354-358.doi:10.3343/alm.2023.0412
12. Jaworska-Posadzy A, Styczynski J, Kubicka M et al. Prognostic value of persistent peripheral blood and bone marrow lymphoblasts on day 15 of therapy in childhood acute lymphoblastic leukemia as detected by flow cytometry. *Anticancer Res*. 2011;31(4):1453-1457. <https://www.ncbi.nlm.nih.gov/pubmed/21508402>
13. Jo I, Chung NG, Lee S et al. Considerations for monitoring minimal residual disease using immunoglobulin clonality in patients with precursor b-cell lymphoblastic leukemia. *Clin Chim Acta*. 2019;488:81-89.doi:10.1016/j.cca.2018.10.037
14. Keegan A, Charest K, Schmidt R et al. Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early



detection of relapsed extramedullary disease. *J Clin Pathol*. 2018;71(7):653-658.doi:10.1136/jclinpath-2017-204828

15. Kotrova M, Volland A, Kehden B et al. Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia. 34 vol. 4 ed; 2020:1154-1157.

16. Liao H, Jiang N, Yang Y et al. Association of minimal residual disease by a single-tube 8-color flow cytometric analysis with clinical outcome in adult b-cell acute lymphoblastic leukemia: A real-world study based on 486 patients. *Arch Pathol Lab Med*. 2023;147(10):1186-1195.doi:10.5858/arpa.2022-0172-OA

17. Logan AC, Vashi N, Faham M et al. Immunoglobulin and t cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. *Biol Blood Marrow Transplant*. 2014;20(9):1307-1313.doi:10.1016/j.bbmt.2014.04.018

18. Mai H, Li Q, Wang G et al. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia. *J Cancer Res Clin Oncol*. 2023;149(7):3259-3266.doi:10.1007/s00432-022-04151-6

19. Mikhailova E, Illarionova O, Komkov A et al. Reliable flow-cytometric approach for minimal residual disease monitoring in patients with b-cell precursor acute lymphoblastic leukemia after cd19-targeted therapy. *Cancers (Basel)*. 2022;14(21):05.doi:10.3390/cancers14215445

20. Momen N, Tario J, Fu K, Qian YW. Multiparameter flow cytometry and clonoseq correlation to evaluate precursor b-lymphoblastic leukemia measurable residual disease. *J Hematop*. 2023;16(2):85-94.doi:10.1007/s12308-023-00544-9

21. Muffly L, Sundaram V, Chen C et al. Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. *Blood Adv*. 2021;5(16):3147-3151.doi:10.1182/bloodadvances.2021004234

22. Pulsipher MA, Carlson C, Langholz B et al. Igh-v(d)j NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk all patients. *Blood*. 2015;125(22):3501-3508.doi:10.1182/blood-2014-12-615757

23. Ravandi F, Jorgensen JL, Thomas DA et al. Detection of may predict the outcome of patients with philadelphia chromosome-positive all treated with tyrosine kinase inhibitors plus chemotherapy. *Blood*. 2013;122(7):1214-1221.doi:10.1182/blood-2012-11-466482

24. Sala Torra O, Othus M, Williamson DW et al. Next-generation sequencing in adult b cell acute lymphoblastic leukemia patients. *Biol Blood Marrow Transplant*. 2017;23(4):691-696.doi:10.1016/j.bbmt.2016.12.639

25. Salina TD, Ferreira YA, Alves EB et al. Role of peripheral blood minimum residual disease at day 8 of induction therapy in high-risk pediatric patients with acute lymphocytic leukemia. *Sci Rep*. 2016;6:31179.doi:10.1038/srep31179

26. Schumich A, Maurer-Granofszky M, Attarbaschi A et al. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric b-cell precursor acute lymphoblastic leukemia in trial aieop-bfm-all 2000. *Pediatr Blood Cancer*. 2019;66(5):e27590.doi:10.1002/pbc.27590

27. Seth N, Mahajan V, Kedia S, Sutar A, Sehgal K. Minimal residual disease (MRD) detection in b- all – experience of a standalone flow cytometry laboratory. *Pediatric Hematology Oncology Journal*. 2021;6(1):26-31.doi:10.1016/j.phoj.2020.12.003

28. Setiadi A, Owen D, Tsang A, Milner R, Vercauteren S. The significance of peripheral blood minimal residual disease to predict early disease response in patients with b-cell acute lymphoblastic leukemia. *Int J Lab Hematol*. 2016;38(5):527-534.doi:10.1111/ijlh.12535



29. Short NJ, Jabbour E, Macaron W et al. Ultrasensitive NGS MRD assessment in ph+ all: Prognostic impact and correlation with rt-pcr for bcr::Abl1. *Am J Hematol*. 2023;98(8):1196-1203.doi:10.1002/ajh.26949
30. Tembhare PR, Subramanian Pg PG, Ghogale S et al. A high-sensitivity 10-color flow cytometric minimal residual disease assay in b-lymphoblastic leukemia/lymphoma can easily achieve the sensitivity of 2-in-10(6) and is superior to standard minimal residual disease assay: A study of 622 patients. *Cytometry B Clin Cytom*. 2020;98(1):57-67.doi:10.1002/cyto.b.21831
31. Theunissen P, Mejstrikova E, Sedek L et al. Standardized flow cytometry for highly sensitive MRD measurements in b-cell acute lymphoblastic leukemia. *Blood*. 2017;129(3):347-357.doi:10.1182/blood-2016-07-726307
32. Volejnikova J, Mejstrikova E, Valova T et al. Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood b-cell precursor acute lymphoblastic leukemia with superior prognosis. *Haematologica*. 2011;96(12):1815-1821.doi:10.3324/haematol.2011.042937
33. Weng XQ, Shen Y, Sheng Y et al. Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult b-acute lymphoblastic leukemia. *Blood Cancer J*. 2013;3(8):e133.doi:10.1038/bcj.2013.31
34. Wood B, Wu D, Crossley B et al. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric b-all. *Blood*. 2018;131(12):1350-1359.doi:10.1182/blood-2017-09-806521
35. Wu D, Emerson RO, Sherwood A et al. Detection of minimal residual disease in b lymphoblastic leukemia by high-throughput sequencing of igh. *Clin Cancer Res*. 2014;20(17):4540-4548.doi:10.1158/1078-0432.CCR-13-3231
36. Wu J, Jia S, Wang C et al. Minimal residual disease detection and evolved igh clones analysis in acute b lymphoblastic leukemia using igh deep sequencing. *Front Immunol*. 2016;7:403.doi:10.3389/fimmu.2016.00403
37. Yan N, Wang ZL, Wang XJ et al. Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with b-cell acute lymphoblastic leukemia. *Cancer Lett*. 2024;598:217104.doi:10.1016/j.canlet.2024.217104
38. Zhao X, Zhao X, Chen H et al. Comparative analysis of flow cytometry and rq-pcr for the detection of minimal residual disease in philadelphia chromosome-positive acute lymphoblastic leukemia after hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2018;24(9):1936-1943.doi:10.1016/j.bbmt.2018.03.015

Disclaimer

The information, data, and draft recommendations provided by the College of American Pathologists are presented for informational and public feedback purposes only.

The draft recommendations and supporting documents will be removed on November 5, 2025.

The draft recommendations along with the public comments received and completed evidence review will be reassessed by the expert panel in order to formulate the final recommendations.

These draft materials should not be stored, adapted, or redistributed in any manner.